To include your compound in the COVID-19 Resource Center, submit it here.

NICE recommends GSK's Strimvelis for ADA-SCID

The U.K.'s NICE issued draft guidance recommending gene therapy Strimvelis (GSK2696273) from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to treat severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) for whom no suitable HLA-matched related stem cell donor

Read the full 363 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers